Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor cells into patients with hematologic disorders with the goal of re-establishing normal hematopoietic and immune function. HCT is classified as autologous or allogeneic based on the origin of hematopoietic cells. Autologous HCT uses the patient’s own cells while allogeneic HCT uses hematopoietic cells from a human leukocyte antigen-compatible donor. Allogeneic HCT is a potentially curative treatment option for patients with certain types of hematologic malignancies, and autologous HCT is primarily used to support patients undergoing high-dose chemotherapy. Advances in HCT methods and supportive care in recent decades have led to improved survival after HCT; however, disease relapse and posttransplant complications still commonly occur in both autologous and allogeneic HCT recipients. Allogeneic HCT recipients may also develop acute and/or chronic graft-versus-host disease (GVHD), which results in immune-mediated cellular injury of several organs. The NCCN Guidelines for Hematopoietic Cell Transplantation focus on recommendations for pretransplant recipient evaluation and the management of GVHD in adult patients with malignant disease.
Individual Disclosures for the NCCN Hematopoietic Cell Transplantation Panel
NiederwieserD, BaldomeroH, SzerJ, et al.. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant2016;51:778–785.
NiederwieserD, BaldomeroH, SzerJ, . Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant 2016;51:778–785.10.1038/bmt.2016.18)| false
MajhailNS, FarniaSH, CarpenterPA, et al.. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant2015;21:1863–1869.
MajhailNS, FarniaSH, CarpenterPA, . Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21:1863–1869.10.1016/j.bbmt.2015.07.03226256941)| false
BensingerWI, MartinPJ, StorerB, et al.. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med2001;344:175–181.
BensingerWI, MartinPJ, StorerB, . Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175–181.1117213910.1056/NEJM200101183440303)| false
AnasettiC, LoganBR, LeeSJ, . Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012;367:1487–1496.10.1056/NEJMoa120351723075175)| false
LeeSJ, LoganB, WesterveltP, et al.. Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial. JAMA Oncol2016;2:1583–1589.
LeeSJ, LoganB, WesterveltP, . Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial. JAMA Oncol 2016;2:1583–1589.10.1001/jamaoncol.2016.252027532508)| false
LuznikL, O’DonnellPV, SymonsHJ, et al.. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant2008;14:641–650.
McDonaldGB, SandmaierBM, MielcarekM, et al.. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts. Ann Intern Med2020;172:229–239.
McDonaldGB, SandmaierBM, MielcarekM, . Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts. Ann Intern Med 2020;172:229–239.10.7326/M19-293631958813)| false
GiebelS, LabopinM, SociéG, et al.. Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica2017;102:139–149.
GiebelS, LabopinM, SociéG, . Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 2017;102:139–149.10.3324/haematol.2016.14563127686376)| false
TrajkovskaI, GeorgievskiB, CevreskaL, et al.. Early and late complications in patients with allogeneic transplantation of hematopoietic stem cell. Open Access Maced J Med Sci2017;5:340–343.
TrajkovskaI, GeorgievskiB, CevreskaL, . Early and late complications in patients with allogeneic transplantation of hematopoietic stem cell. Open Access Maced J Med Sci 2017;5:340–343.2869875410.3889/oamjms.2017.038)| false
TanakaY, KurosawaS, TajimaK, et al.. Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant2016;51:553–559.
TanakaY, KurosawaS, TajimaK, . Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2016;51:553–559.10.1038/bmt.2015.33026752142)| false
WingardJR, MajhailNS, BrazauskasR, et al.. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol2011;29:2230–2239.
MarchesiF, PimpinelliF, Di DomenicoEG, et al.. Association between CMV and invasive fungal infections after autologous stem cell transplant in lymphoproliferative malignancies: opportunistic partnership or cause-effect relationship?Int J Mol Sci2019;20:1373.
MarchesiF, PimpinelliF, Di DomenicoEG, . Association between CMV and invasive fungal infections after autologous stem cell transplant in lymphoproliferative malignancies: opportunistic partnership or cause-effect relationship?Int J Mol Sci 2019;20:1373.10.3390/ijms20061373)| false
JantunenE, ItäläM, LehtinenT, et al.. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol2006;76:245–250.
PalumboA, CavalloF, GayF, . Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 2014;371:895–905.2518486210.1056/NEJMoa1402888)| false
ChildJA, MorganGJ, DaviesFE, . High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875–1883.1273628010.1056/NEJMoa022340)| false
FermandJP, KatsahianS, DivineM, et al.. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol2005;23:9227–9233.
FermandJP, KatsahianS, DivineM, . High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005;23:9227–9233.10.1200/JCO.2005.03.0551)| false
AttalM, HarousseauJL, StoppaAM, et al.. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med1996;335:91–97.
AttalM, HarousseauJL, StoppaAM, . A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996;335:91–97.10.1056/NEJM1996071133502048649495)| false
ShahN, CallanderN, GangulyS, et al.. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant2015;21:1155–1166.
ShahN, CallanderN, GangulyS, . Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21:1155–1166.2576979410.1016/j.bbmt.2015.03.002)| false
PeralesMA, CeberioI, ArmandP, et al.. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant2015;21:971–983.
PeralesMA, CeberioI, ArmandP, . Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2015;21:971–983.10.1016/j.bbmt.2015.02.02225773017)| false
PhilipT, GuglielmiC, HagenbeekA, et al.. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med1995;333:1540–1545.
PhilipT, GuglielmiC, HagenbeekA, . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333:1540–1545.747716910.1056/NEJM199512073332305)| false
OlianskyDM, CzuczmanM, FisherRI, et al.. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant2011;17:20–47.
OlianskyDM, CzuczmanM, FisherRI, . The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant 2011;17:20–47.10.1016/j.bbmt.2010.07.00820656046)| false
OlianskyDM, GordonLI, KingJ, et al.. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant2010;16:443–468.
OlianskyDM, GordonLI, KingJ, . The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2010;16:443–468.10.1016/j.bbmt.2010.01.00820114084)| false
EinhornLH, WilliamsSD, ChamnessA, . High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007;357:340–348.10.1056/NEJMoa06774917652649)| false
HamidAA, MarktSC, VicierC, et al.. Autologous stem-cell transplantation outcomes for relapsed metastatic germ-cell tumors in the modern era. Clin Genitourin Cancer2019;17:58–64.e1.
HamidAA, MarktSC, VicierC, . Autologous stem-cell transplantation outcomes for relapsed metastatic germ-cell tumors in the modern era. Clin Genitourin Cancer 2019;17:58–64.e1.10.1016/j.clgc.2018.09.00930309761)| false
DunkelIJ, GardnerSL, GarvinJH, Jr., et al.. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. Neuro-oncol2010;12:297–303.
IllerhausG, MüllerF, FeuerhakeF, et al.. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica2008;93:147–148.
IllerhausG, MüllerF, FeuerhakeF, . High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008;93:147–148.1816680310.3324/haematol.11771)| false
KasendaB, IhorstG, SchroersR, et al.. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia2017;31:2623–2629.
KasendaB, IhorstG, SchroersR, . High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia 2017;31:2623–2629.10.1038/leu.2017.170)| false
DeFilippZ, LiS, El-JawahriA, et al.. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer2017;123:3073–3079.
DeFilippZ, LiS, El-JawahriA, . High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer 2017;123:3073–3079.10.1002/cncr.3069528369839)| false
SoussainC, Hoang-XuanK, TaillandierL, et al.. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol2008;26:2512–2518.
SoussainC, Hoang-XuanK, TaillandierL, . Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol 2008;26:2512–2518.1841364110.1200/JCO.2007.13.5533)| false
De RosaL, LalleM, PandolfiA, et al.. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin’s lymphoma in first complete remission. Ann Hematol2002;81:575–581.
De RosaL, LalleM, PandolfiA, . Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin’s lymphoma in first complete remission. Ann Hematol 2002;81:575–581.10.1007/s00277-002-0528-6)| false
BiermanPJ, SweetenhamJW, LoberizaFR, Jr., et al.. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin’s lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol2003;21:3744–3753.
BiermanPJ, SweetenhamJW, LoberizaFR, Jr., . Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin’s lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003;21:3744–3753.)| false
WeisdorfD, EapenM, RuggeriA, et al.. Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol Blood Marrow Transplant2014;20:816–822.
WeisdorfD, EapenM, RuggeriA, . Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis. Biol Blood Marrow Transplant 2014;20:816–822.2458278210.1016/j.bbmt.2014.02.020)| false
RashidiA, HamadaniM, ZhangMJ, et al.. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv2019;3:1826–1836.
RashidiA, HamadaniM, ZhangMJ, . Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv 2019;3:1826–1836.3120117010.1182/bloodadvances.2019000050)| false
MeybodiMA, CaoW, LuznikL, et al.. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv2019;3:2581–2585.
BazarbachiA, BoumendilA, FinelH, et al.. Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol2019;188:745–756.
BazarbachiA, BoumendilA, FinelH, . Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study. Br J Haematol 2019;188:745–756.3149888310.1111/bjh.16182)| false
GluckmanE, BroxmeyerHA, AuerbachAD, et al.. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med1989;321:1174–1178.
GluckmanE, BroxmeyerHA, AuerbachAD, . Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174–1178.10.1056/NEJM198910263211707)| false
WagnerJE, RosenthalJ, SweetmanR, et al.. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood1996;88:795–802.
BarkerJN, WeisdorfDJ, DeForTE, et al.. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood2005;105:1343–1347.
BarkerJN, WeisdorfDJ, DeForTE, . Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005;105:1343–1347.10.1182/blood-2004-07-271715466923)| false
LaughlinMJ, EapenM, RubinsteinP, et al.. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med2004;351:2265–2275.
LaughlinMJ, EapenM, RubinsteinP, . Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004;351:2265–2275.1556454310.1056/NEJMoa041276)| false
MarksDI, WooKA, ZhongX, et al.. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica2014;99:322–328.
MarksDI, WooKA, ZhongX, . Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica 2014;99:322–328.10.3324/haematol.2013.09419324056817)| false
RochaV, LabopinM, SanzG, et al.. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med2004;351:2276–2285.
RochaV, LabopinM, SanzG, . Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004;351:2276–2285.10.1056/NEJMoa04146915564544)| false
YanadaM, MatsuoK, SuzukiT, et al.. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer2006;106:2657–2663.
YanadaM, MatsuoK, SuzukiT, . Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006;106:2657–2663.1670359710.1002/cncr.21932)| false
de WitteT, BowenD, RobinM, et al.. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood2017;129:1753–1762.
de WitteT, BowenD, RobinM, . Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood 2017;129:1753–1762.10.1182/blood-2016-06-724500)| false
Kharfan-DabajaMA, KumarA, HamadaniM, et al.. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant2016;22:2117–2125.
Kharfan-DabajaMA, KumarA, HamadaniM, . Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2016;22:2117–2125.10.1016/j.bbmt.2016.09.013)| false
BrunoB, RottaM, PatriarcaF, et al.. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood2009;113:3375–3382.
BrunoB, RottaM, PatriarcaF, . Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009;113:3375–3382.1906472410.1182/blood-2008-07-167379)| false
ShanavasM, MessnerHA, AtenafuEG, et al.. Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning. Bone Marrow Transplant2014;49:1162–1169.
SuredaA, RobinsonS, CanalsC, et al.. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol2008;26:455–462.
SuredaA, RobinsonS, CanalsC, . Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:455–462.10.1200/JCO.2007.13.2415)| false
CorradiniP, DoderoA, ZallioF, et al.. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol2004;22:2172–2176.
MufflyL, PasquiniMC, MartensM, et al.. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood2017;130:1156–1164.
MufflyL, PasquiniMC, MartensM, . Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood 2017;130:1156–1164.2867402710.1182/blood-2017-03-772368)| false
SorrorML, MarisMB, StorbR, et al.. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood2005;106:2912–2919.
SorrorML, LoganBR, ZhuX, et al.. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a Center for International Blood and Marrow Transplant research study. Biol Blood Marrow Transplant2015;21:1479–1487.
SorrorML, LoganBR, ZhuX, . Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a Center for International Blood and Marrow Transplant research study. Biol Blood Marrow Transplant 2015;21:1479–1487.10.1016/j.bbmt.2015.04.00425862591)| false
ElSawyM, StorerBE, PulsipherMA, et al.. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol2015;170:574–583.
ElSawyM, StorerBE, PulsipherMA, . Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol 2015;170:574–583.2594580710.1111/bjh.13476)| false
SaadA, MahindraA, ZhangMJ, et al.. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant2014;20:402–408.
SaadA, MahindraA, ZhangMJ, . Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2014;20:402–408.2434239410.1016/j.bbmt.2013.12.557)| false
SorrorML, StorbRF, SandmaierBM, et al.. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol2014;32:3249–3256.
Foundation for the Accreditation of Cellular Therapy and Joint Accreditation Committee-ISCT and EBMT. FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, 7th Ed.Omaha, NE:;University of Nebraska Medical Center;2017.
Foundation for the Accreditation of Cellular Therapy and Joint Accreditation Committee-ISCT and EBMT. FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, 7th Ed.Omaha, NE:;University of Nebraska Medical Center;2017.)| false
FilipovichAH, WeisdorfD, PavleticS, et al.. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant2005;11:945–956.
FilipovichAH, WeisdorfD, PavleticS, . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945–956.10.1016/j.bbmt.2005.09.004)| false
AraiS, AroraM, WangT, et al.. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant2015;21:266–274.
AraiS, AroraM, WangT, . Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 2015;21:266–274.10.1016/j.bbmt.2014.10.02125445023)| false
FlowersME, InamotoY, CarpenterPA, et al.. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood2011;117:3214–3219.
FlowersME, InamotoY, CarpenterPA, . Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011;117:3214–3219.2126315610.1182/blood-2010-08-302109)| false
JagasiaMH, GreinixHT, AroraM, et al.. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant2015;21:389–401.
JagasiaMH, GreinixHT, AroraM, . National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant 2015;21:389–401.10.1016/j.bbmt.2014.12.001)| false
MartinPJ, RizzoJD, WingardJR, et al.. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant2012;18:1150–1163.
MartinPJ, RizzoJD, WingardJR, . First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012;18:1150–1163.10.1016/j.bbmt.2012.04.00522510384)| false
RossWA, GhoshS, DekovichAA, et al.. Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. Am J Gastroenterol2008;103:982–989.
GlucksbergH, StorbR, FeferA, et al.. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation1974;18:295–304.
GlucksbergH, StorbR, FeferA, . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974;18:295–304.10.1097/00007890-197410000-000014153799)| false
MartinoR, RomeroP, SubiráM, et al.. Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry. Bone Marrow Transplant1999;24:283–287.
MartinoR, RomeroP, SubiráM, . Comparison of the classic Glucksberg criteria and the IBMTR Severity Index for grading acute graft-versus-host disease following HLA-identical sibling stem cell transplantation. International Bone Marrow Transplant Registry. Bone Marrow Transplant 1999;24:283–287.1045536710.1038/sj.bmt.1701899)| false
MacMillanML, DeForTE, WeisdorfDJ. What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol2012;157:732–741.
MacMillanML, DeForTE, WeisdorfDJ. What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol 2012;157:732–741.2248635510.1111/j.1365-2141.2012.09114.x)| false
MacMillanML, RobinM, HarrisAC, et al.. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant2015;21:761–767.
HarrisAC, YoungR, DevineS, et al.. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant2016;22:4–10.
HarrisAC, YoungR, DevineS, . International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant 2016;22:4–10.10.1016/j.bbmt.2015.09.001)| false
SchoemansHM, LeeSJ, FerraraJL, et al.. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant2018;53:1401–1415.
SchoemansHM, LeeSJ, FerraraJL, . EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 2018;53:1401–1415.2987212810.1038/s41409-018-0204-7)| false
AliAM, DiPersioJF, SchroederMA. The role of biomarkers in the diagnosis and risk stratification of acute graft-versus-host disease: a systematic review. Biol Blood Marrow Transplant2016;22:1552–1564.
AliAM, DiPersioJF, SchroederMA. The role of biomarkers in the diagnosis and risk stratification of acute graft-versus-host disease: a systematic review. Biol Blood Marrow Transplant 2016;22:1552–1564.2715805010.1016/j.bbmt.2016.04.022)| false
LevineJE, BraunTM, HarrisAC, et al.. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol2015;2:e21–e29.
LevineJE, BraunTM, HarrisAC, . A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol 2015;2:e21–e29.2668742510.1016/S2352-3026(14)00035-0)| false
MielcarekM, FurlongT, StorerBE, et al.. Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica2015;100:842–848.
MielcarekM, FurlongT, StorerBE, . Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica 2015;100:842–848.10.3324/haematol.2014.11847125682602)| false
AlousiAM, WeisdorfDJ, LoganBR, et al.. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood2009;114:511–517.
AlousiAM, WeisdorfDJ, LoganBR, . Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009;114:511–517.1944365910.1182/blood-2009-03-212290)| false
Bolaños-MeadeJ, LoganBR, AlousiAM, et al.. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood2014;124:3221–3227., quiz 3335.
PidalaJ, HamadaniM, DawsonP, et al.. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood2020;135:97–107.
PidalaJ, HamadaniM, DawsonP, . Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood 2020;135:97–107.10.1182/blood.201900312531738834)| false
JagasiaM, AliH, SchroederMA, et al.. Ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease: results from the phase 2 REACH1 trial. Biol Blood Marrow Transplant2019;25(Suppl):S52.
JagasiaM, AliH, SchroederMA, . Ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease: results from the phase 2 REACH1 trial. Biol Blood Marrow Transplant 2019;25(Suppl):S52.10.1016/j.bbmt.2018.12.130)| false
PidalaJ, KurlandB, ChaiX, et al.. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood2011;117:4651–4657.
PidalaJ, KurlandB, ChaiX, . Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011;117:4651–4657.10.1182/blood-2010-11-31950921355084)| false
LeeSJ, WolffD, KitkoC, et al.. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant2015;21:984–999.
LeeSJ, WolffD, KitkoC, . Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant 2015;21:984–999.10.1016/j.bbmt.2015.02.025)| false
CarpenterPA, KitkoCL, EladS, et al.. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant2015;21:1167–1187.
CarpenterPA, KitkoCL, EladS, . National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 2015;21:1167–1187.10.1016/j.bbmt.2015.03.024)| false
ShulmanHM, CardonaDM, GreensonJK, et al.. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant2015;21:589–603.
ShulmanHM, CardonaDM, GreensonJK, . NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transplant 2015;21:589–603.10.1016/j.bbmt.2014.12.031)| false
PaczesnyS, HakimFT, PidalaJ, et al.. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2014 biomarker working group report. Biol Blood Marrow Transplant2015;21:780–792.
PaczesnyS, HakimFT, PidalaJ, . National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: III. The 2014 biomarker working group report. Biol Blood Marrow Transplant 2015;21:780–792.10.1016/j.bbmt.2015.01.003)| false
BergeronA, ChevretS, GranataA, et al.. Effect of azithromycin on airflow decline-free survival after allogeneic hematopoietic stem cell transplant: the ALLOZITHRO randomized clinical trial. JAMA2017;318:557–566.
MacDonaldKPA, BettsBC, CourielD. Emerging therapeutics for the control of chronic graft-versus-host disease. Biol Blood Marrow Transplant2018;24:19–26.
MacDonaldKPA, BettsBC, CourielD. Emerging therapeutics for the control of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2018;24:19–26.10.1016/j.bbmt.2017.10.00629032060)| false
U.S. Food and Drug Administration. Alemtuzumab Package Insert. 2001. Accessed January 14, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103948s5070lbl.pdf.)| false
KhouriIF, AlbitarM, SalibaRM, et al.. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant2004;33:833–837.
Gómez-AlmaguerD, Ruiz-ArgüellesGJ, del Carmen Tarín-ArzagaL, et al.. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant2008;14:10–15.
Gómez-AlmaguerD, Ruiz-ArgüellesGJ, del Carmen Tarín-ArzagaL, . Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2008;14:10–15.1815895610.1016/j.bbmt.2007.08.052)| false
SchnitzlerM, HasskarlJ, EggerM, et al.. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant2009;15:910–918.
SchnitzlerM, HasskarlJ, EggerM, . Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009;15:910–918.10.1016/j.bbmt.2009.04.00219589480)| false
MagenauJM, GoldsteinSC, PeltierD, et al.. α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood2018;131:1372–1379.
PyeA, TurnerAM. Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency. Expert Opin Investig Drugs 2019;28:891–902.3155093810.1080/13543784.2019.1672656)| false
AraiY, JoT, MatsuiH, et al.. Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Leuk Lymphoma2017;58:1840–1848.
AlousiAM, BrammerJE, SalibaRM, et al.. Phase II trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies. Biol Blood Marrow Transplant2015;21:906–912.
CzerwT, LabopinM, GiebelS, et al.. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. Cancer2018;124:2523–2533.
CzerwT, LabopinM, GiebelS, . Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT. Cancer 2018;124:2523–2533.29603136)| false
KrögerN, SolanoC, WolschkeC, . Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 2016;374:43–53.10.1056/NEJMoa150600226735993)| false
KumarA, ReljicT, HamadaniM, et al.. Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. Bone Marrow Transplant2019;54:1094–1106.
ZiakasPD, ZervouFN, ZacharioudakisIM, et al.. Graft-versus-host disease prophylaxis after transplantation: a network meta-analysis. PLoS One2014;9:e114735.
U.S. Food and Drug Administration. Thymoglobulin Package Insert. 1998. Accessed February 28, 2020. Available at: https://www.fda.gov/media/74641/download)| false
U.S. Food and Drug Administration. Atgam Package Insert. 1981. Accessed February 28, 2020. Available at: https://www.fda.gov/media/78206/download)| false
AliR, RamdialJ, AlgazeS, et al.. The role of anti-thymocyte globulin or alemtuzumab-based serotherapy in the prophylaxis and management of graft-versus-host disease. Biomedicines2017;5:57.
AliR, RamdialJ, AlgazeS, . The role of anti-thymocyte globulin or alemtuzumab-based serotherapy in the prophylaxis and management of graft-versus-host disease. Biomedicines 2017;5:57.10.3390/biomedicines5040067)| false
U.S. Food and Drug Administration. Basiliximab Package Insert. 1998. Accessed January 14, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/basnov051298lb.pdf)| false
Schmidt-HieberM, FietzT, KnaufW, et al.. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol2005;130:568–574.
U.S. Food and Drug Administration. Tacrolimus Package Insert. 1994. Accessed February 6, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050709s031lbl.pdf)| false
U.S. Food and Drug Administration. Cyclosporine Package Insert. 1983. Accessed February 6, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050573s035,050574s043,050625s049lbl.pdf)| false
KandaY, KobayashiT, MoriT, et al.. A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. Bone Marrow Transplant2016;51:103–109.
KandaY, KobayashiT, MoriT, . A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation. Bone Marrow Transplant 2016;51:103–109.2643706310.1038/bmt.2015.222)| false
MielcarekM, FurlongT, O’DonnellPV, et al.. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood2016;127:1502–1508.
TörlénJ, RingdénO, Garming-LegertK, et al.. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. Haematologica2016;101:1417–1425.
Al-KadhimiZ, GulZ, AbidiM, et al.. Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention. Bone Marrow Transplant2017;52:1304–1310.
Al-KadhimiZ, GulZ, AbidiM, . Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention. Bone Marrow Transplant 2017;52:1304–1310.10.1038/bmt.2017.95)| false
CutlerC, LoganB, NakamuraR, et al.. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood2014;124:1372–1377.
CutlerC, LoganB, NakamuraR, . Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood 2014;124:1372–1377.10.1182/blood-2014-04-56716424982504)| false
DeegHJ, LoughranTP, Jr., StorbR, et al.. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation1985;40:162–166.
DeegHJ, LoughranTP, Jr., StorbR, . Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 1985;40:162–166.10.1097/00007890-198508000-000113895622)| false
KanamaruA, TakemotoY, KakishitaE, et al.. FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplant1995;15:885–889.
KanamaruA, TakemotoY, KakishitaE, . FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT Study Group. Bone Marrow Transplant 1995;15:885–889.)| false
XhaardA, LaunayM, Sicre de FontbruneF, et al.. A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor. Bone Marrow Transplant2020;55:86–92.
XhaardA, LaunayM, Sicre de FontbruneF, . A monocentric study of steroid-refractory acute graft-versus-host disease treatment with tacrolimus and mTOR inhibitor. Bone Marrow Transplant 2020;55:86–92.3141331310.1038/s41409-019-0633-y)| false
U.S. Food and Drug Administration. Etanercept Package Insert. 1998. Accessed January 14, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103795s5569lbl.pdf)| false
BuscaA, LocatelliF, MarmontF, et al.. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol2007;82:45–52.
Abu-DalleI, ReljicT, NishihoriT, et al.. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. Biol Blood Marrow Transplant2014;20:1677–1686.
AlcindorT, GorgunG, MillerKB, et al.. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood2001;98:1622–1625.
GreinixHT, KnoblerRM, WorelN, et al.. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica2006;91:405–408.
GreinixHT, KnoblerRM, WorelN, . The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 2006;91:405–408.16531267)| false
SakellariI, GavriilakiE, BatsisI, et al.. Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: Prospective single-center study. J Clin Apher2018;33:654–660.
ZhangH, ChenR, ChengJ, et al.. Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD. Patient Prefer Adherence2015;9:105–111.
ZhangH, ChenR, ChengJ, . Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD. Patient Prefer Adherence 2015;9:105–111.25653504)| false
U.S. Food and Drug Administration. Infliximab Package Insert. 1998. Accessed January 29, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf)| false
YalnizFF, HefaziM, McCulloughK, et al.. Safety and efficacy of infliximab therapy in the setting of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant2017;23:1478–1484.
YalnizFF, HefaziM, McCulloughK, . Safety and efficacy of infliximab therapy in the setting of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2017;23:1478–1484.2849564110.1016/j.bbmt.2017.05.001)| false
ArmandP, KimHT, SainvilMM, et al.. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol2016;173:96–104.
ArmandP, KimHT, SainvilMM, . The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol 2016;173:96–104.2672944810.1111/bjh.13931)| false
KornblitB, MaloneyDG, StorerBE, et al.. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica2014;99:1624–1631.
KornblitB, MaloneyDG, StorerBE, . A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica 2014;99:1624–1631.2508535710.3324/haematol.2014.108340)| false
PidalaJ, KimJ, AlsinaM, et al.. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. Haematologica2015;100:970–977.
WangL, GuZ, ZhaiR, et al.. The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. Transfusion2015;55:2134–2141.
WangL, GuZ, ZhaiR, . The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. Transfusion 2015;55:2134–2141.2585772510.1111/trf.13110)| false
BenitoAI, FurlongT, MartinPJ, et al.. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation2001;72:1924–1929.
HodaD, PidalaJ, Salgado-VilaN, et al.. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant2010;45:1347–1351.
AllisonAC, EuguiEM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85–118.1087828510.1016/S0162-3109(00)00188-0)| false
U.S. Food and Drug Administration. Mycophenolate Mofetil Package Insert. 1995. Accessed January 29, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050722s035,050723s035,050758s033,050759s041lbl.pdf)| false
FurlongT, MartinP, FlowersME, . Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009;44:739–748.1937751510.1038/bmt.2009.76)| false
KimJG, SohnSK, KimDH, et al.. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol2004;73:56–61.
KimJG, SohnSK, KimDH, . Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 2004;73:56–61.10.1111/j.1600-0609.2004.00247.x15182339)| false
PidalaJ, KimJ, PerkinsJ, et al.. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant2010;45:919–924.
PidalaJ, KimJ, PerkinsJ, . Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant 2010;45:919–924.10.1038/bmt.2009.25219767783)| false
U.S. Food and Drug Administration. Pentostatin Package Insert. 2007. Accessed January 29, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020122s015lbl.pdf)| false
RagonBK, MehtaRS, GulbisAM, et al.. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant2018;53:315–325.
RagonBK, MehtaRS, GulbisAM, . Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 2018;53:315–325.10.1038/s41409-017-0034-z29269797)| false
SchmittT, LuftT, HegenbartU, et al.. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. Bone Marrow Transplant2011;46:580–585.
SchmittT, LuftT, HegenbartU, . Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. Bone Marrow Transplant 2011;46:580–585.10.1038/bmt.2010.14620562925)| false
PidalaJ, KimJ, Roman-DiazJ, et al.. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Ann Transplant2010;15:21–29.
PidalaJ, KimJ, Roman-DiazJ, . Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Ann Transplant 2010;15:21–29.21183872)| false
PoiMJ, HofmeisterCC, JohnstonJS, et al.. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Clin Pharmacokinet2013;52:705–712.
PoiMJ, HofmeisterCC, JohnstonJS, . Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Clin Pharmacokinet 2013;52:705–712.2358853610.1007/s40262-013-0064-7)| false
JagasiaM, ZeiserR, ArbushitesM, et al.. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy2018;10:391–402.
JagasiaM, ZeiserR, ArbushitesM, . Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy 2018;10:391–402.2931683710.2217/imt-2017-0156)| false
U.S. Food and Drug Administration. FDA approves ruxolitinib for acute graft-versus-host disease. 2019. Accessed January 24, 2020. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-acute-graft-versus-host-disease)| false
ZeiserR, BurchertA, LengerkeC, et al.. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia2015;29:2062–2068.
U.S. Food and Drug Administration. Tocilizumab Package Insert. 2010. Accessed January 28, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125276s114lbl.pdf)| false
ImamuraM, HashinoS, KobayashiH, et al.. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant1994;13:745–751.
ImamuraM, HashinoS, KobayashiH, . Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant 1994;13:745–751.7920309)| false
CavetJ, DickinsonAM, NordenJ, et al.. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood2001;98:1594–1600.
GanetskyA, FreyNV, HexnerEO, et al.. Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. Bone Marrow Transplant2019;54:212–217.
GanetskyA, FreyNV, HexnerEO, . Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. Bone Marrow Transplant 2019;54:212–217.2979542910.1038/s41409-018-0236-z)| false
GergisU, ArnasonJ, YantissR, et al.. Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. J Clin Oncol2010;28:e602–e604.
GergisU, ArnasonJ, YantissR, . Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease. J Clin Oncol 2010;28:e602–e604.10.1200/JCO.2010.29.1682)| false
YucebayF, MatthewsC, PutoM, et al.. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience. Leuk Lymphoma2019;60:2223–2229.
DrobyskiWR, PasquiniM, KovatovicK, et al.. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant2011;17:1862–1868.
FløisandY, LazarevicVL, MaertensJ, et al.. Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review. Biol Blood Marrow Transplant2019;25:720–727.
FløisandY, LazarevicVL, MaertensJ, . Safety and effectiveness of vedolizumab in patients with steroid-refractory gastrointestinal acute graft-versus-host disease: a retrospective record review. Biol Blood Marrow Transplant 2019;25:720–727.10.1016/j.bbmt.2018.11.01330468919)| false
DanyleskoI, BukauskasA, PaulsonM, et al.. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. Bone Marrow Transplant2019;54:987–993.
DanyleskoI, BukauskasA, PaulsonM, . Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease. Bone Marrow Transplant 2019;54:987–993.10.1038/s41409-018-0364-530356163)| false
U.S. Food and Drug Administration. Natalizumab Package Insert. 2004. Accessed March 2, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125104s0576lbl.pdf)| false
U.S. Food and Drug Administration. Vedolizumab Package Insert. 2014. Accessed March 2, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf)| false
U.S. Food and Drug Administration. Abatacept Package Insert. 2005. Accessed January 29, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125118s171lbl.pdf)| false
NikiforowS, KimHT, BindraB, et al.. Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant2013;19:804–811.
NikiforowS, KimHT, BindraB, . Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2013;19:804–811.10.1016/j.bbmt.2013.02.00923416855)| false
Gutiérrez-AguirreCH, Cantú-RodríguezOG, Borjas-AlmaguerOD, et al.. Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. Haematologica2012;97:717–722.
TzakisAG, Abu-ElmagdK, FungJJ, et al.. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc1991;23:3225–3227.
TzakisAG, Abu-ElmagdK, FungJJ, . FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. Transplant Proc 1991;23:3225–3227.1721416)| false
Carnevale-SchiancaF, MartinP, SullivanK, et al.. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant2000;6:613–620.
FlowersME, ApperleyJF, van BesienK, et al.. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood2008;112:2667–2674.
FlowersME, ApperleyJF, van BesienK, . A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood 2008;112:2667–2674.10.1182/blood-2008-03-14148118621929)| false
MalikMI, LitzowM, HoganW, et al.. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res2014;49:100–106.
MalikMI, LitzowM, HoganW, . Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. Blood Res 2014;49:100–106.2502501110.5045/br.2014.49.2.100)| false
U.S. Food and Drug Administration. Hydroxychloroquine Package Insert. 1955. Accessed January 31, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/009768Orig1s051lbl.pdf)| false
WolffD, SchleuningM, von HarsdorfS, et al.. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant2011;17:1–17.
WolffD, SchleuningM, von HarsdorfS, . Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011;17:1–17.2068525510.1016/j.bbmt.2010.05.011)| false
GilmanAL, ChanKW, MogulA, et al.. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant2000;6(3, 3A)327–334.
NavajasEV, KremaH, HammoudiDS, et al.. Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. Can J Ophthalmol2015;50:442–450.
NavajasEV, KremaH, HammoudiDS, . Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. Can J Ophthalmol 2015;50:442–450.2665130410.1016/j.jcjo.2015.08.003)| false
DubovskyJA, BeckwithKA, NatarajanG, et al.. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood2013;122:2539–2549.
DubovskyJA, BeckwithKA, NatarajanG, . Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013;122:2539–2549.10.1182/blood-2013-06-507947)| false
U.S. Food and Drug Administration. Ibrutnib Package Insert. 2013. Accessed February 3, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210563s000lbl.pdf)| false
WallerEK, MiklosD, CutlerC, et al.. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b/2 study. Biol Blood Marrow Transplant2019;25:2002–2007.
U.S. Food and Drug Administration. Imatinib Package Insert. 2001. Accessed February 3, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf)| false
ChenGL, AraiS, FlowersME, et al.. A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood2011;118:4070–4078.
ChenGL, AraiS, FlowersME, . A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood 2011;118:4070–4078.10.1182/blood-2011-03-34169321828142)| false
AraiS, PidalaJ, PusicI, et al.. A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res2016;22:319–327.
AraiS, PidalaJ, PusicI, . A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res 2016;22:319–327.2637803310.1158/1078-0432.CCR-15-1443)| false
OlivieriA, CimminielloM, CorradiniP, et al.. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood2013;122:4111–4118.
KorethJ, KimHT, JonesKT, et al.. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood2016;128:130–137.
KorethJ, MatsuokaK, KimHT, . Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365:2055–2066.10.1056/NEJMoa110818822129252)| false
WhangboJS, KimHT, MirkovicN, et al.. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv2019;3:2550–2561.
U.S. Food and Drug Administration. Methotrexate Package Insert. 1972. Accessed February 4, 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011719s117lbl.pdf)| false
GiacconeL, MartinP, CarpenterP, et al.. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant2005;36:337–341.
GiacconeL, MartinP, CarpenterP, . Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant 2005;36:337–341.1596829610.1038/sj.bmt.1705022)| false
de LavalladeH, MohtyM, FaucherC, et al.. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica2006;91:1438–1440.
de LavalladeH, MohtyM, FaucherC, . Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica 2006;91:1438–1440.)| false
